Castalian Partners LLC purchased a new stake in Inhibrx, Inc. (NASDAQ:INBX - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 191,533 shares of the company's stock, valued at approximately $2,950,000. Inhibrx makes up 1.5% of Castalian Partners LLC's investment portfolio, making the stock its 15th biggest holding. Castalian Partners LLC owned approximately 1.32% of Inhibrx at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. PNC Financial Services Group Inc. purchased a new position in shares of Inhibrx in the 4th quarter worth approximately $28,000. Natixis acquired a new position in Inhibrx during the 4th quarter valued at about $31,000. JPMorgan Chase & Co. raised its stake in Inhibrx by 47.8% in the fourth quarter. JPMorgan Chase & Co. now owns 7,592 shares of the company's stock valued at $117,000 after buying an additional 2,457 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in Inhibrx in the fourth quarter worth about $47,000. Finally, New York State Common Retirement Fund acquired a new stake in Inhibrx in the fourth quarter worth about $53,000. Hedge funds and other institutional investors own 82.46% of the company's stock.
Analyst Ratings Changes
Separately, JMP Securities reissued a "market perform" rating on shares of Inhibrx in a research report on Wednesday, January 22nd.
Get Our Latest Stock Report on INBX
Inhibrx Trading Down 1.5 %
Shares of NASDAQ:INBX traded down $0.18 during trading on Monday, hitting $11.97. The stock had a trading volume of 72,872 shares, compared to its average volume of 193,438. Inhibrx, Inc. has a 12-month low of $10.80 and a 12-month high of $34.75. The stock has a 50-day simple moving average of $12.97 and a two-hundred day simple moving average of $13.93.
Inhibrx (NASDAQ:INBX - Get Free Report) last released its quarterly earnings data on Monday, March 17th. The company reported ($3.09) EPS for the quarter, missing the consensus estimate of ($2.88) by ($0.21). The firm had revenue of $0.10 million for the quarter. Equities analysts predict that Inhibrx, Inc. will post 104.88 EPS for the current year.
About Inhibrx
(
Free Report)
Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
Recommended Stories
Before you consider Inhibrx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inhibrx wasn't on the list.
While Inhibrx currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
